Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers
datasetposted on 08.10.2015, 00:00 by Venkatram R. Atigadda, Gang Xia, Anil Deshpande, Lizhi Wu, Natalia Kedishvili, Craig D. Smith, Helen Krontiras, Kirby I. Bland, Clinton J. Grubbs, Wayne J. Brouillette, Donald D. Muccio
(2E,4E,6Z,8Z)-8-(3′,4′-Dihydro-1′(2H)-naphthalen-1′-ylidene)-3,7-dimethyl-2,3,6-octatrienoinic acid (UAB30) is currently undergoing clinical evaluation as a novel cancer prevention agent. In efforts to develop even more highly potent rexinoids that prevent breast cancer without toxicity, we further explore here the structure–activity relationship of two separate classes of rexinoids. UAB30 belongs to the class II rexinoids and possesses a 9Z-tetraenoic acid chain bonded to a tetralone ring, whereas the class I rexinoids contain the same 9Z-tetraenoic acid chain bonded to a disubstituted cyclohexenyl ring. Among the 12 class I and class II rexinoids evaluated, the class I rexinoid 11 is most effective in preventing breast cancers in an in vivo rat model alone or in combination with tamoxifen. Rexinoid 11 also reduces the size of established tumors and exhibits a therapeutic effect. However, 11 induces hypertriglyceridemia at its effective dose. On the other hand rexinoid 10 does not increase triglyceride levels while being effective in the in vivo chemoprevention assay. X-ray studies of four rexinoids bound to the ligand binding domain of the retinoid X receptor reveal key structural aspects that enhance potency as well as those that enhance the synthesis of lipids.
Read the peer-reviewed publication
increase triglyceride levelsretinoid X receptorConformationally Defined Rexinoidsrexinoid 11acidclass II rexinoidshand rexinoid 10vivo rat modeldisubstituted cyclohexenyl ringbreast cancertetralone ringvivo chemoprevention assaynovel cancer prevention agent12 classbreast cancersRexinoid 11UAB 30ligand binding domain